Annovis Bio Inc. (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing buntanetap for Alzheimer's disease and Parkinson's disease, announced it has regained compliance with New York Stock Exchange continued listing standards. The company implemented corrective measures to restore its market capitalization and stockholders' equity above required thresholds, allowing its common stock to continue trading on the NYSE under the ticker symbol ANVS.
The NYSE had previously notified Annovis of non-compliance due to its market capitalization and stockholders' equity falling below the minimum requirements. By addressing these deficiencies, Annovis has secured its listing status, which is critical for maintaining investor confidence and access to capital markets. This development removes a significant overhang on the stock and allows the company to focus on its clinical programs without the distraction of a potential delisting.
Annovis is headquartered in Malvern, Pennsylvania, and is dedicated to developing treatments for neurodegenerative diseases. Its lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients.
The company is currently conducting Phase 3 clinical trials for buntanetap in Alzheimer's disease and Parkinson's disease. Positive results from these trials could represent a major advancement in the treatment of these debilitating conditions, which affect millions of patients worldwide. Regaining NYSE compliance ensures that Annovis can continue to fund and execute its clinical development plans without interruption.
For more information about Annovis Bio and its pipeline, visit the company's website at www.annovisbio.com. The latest news and updates relating to ANVS are available in the company's newsroom at https://ibn.fm/ANVS.